1-12 of 12
Maneesh Tandon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Glofitamab in Combination with Polatuzumab Vedotin Maintains Durable Responses and a Manageable Safety Profile in Patients with Heavily Pre-Treated Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) Including High-Grade B-Cell Lymphoma (HGBCL): Extended Follow-up of a Phase Ib/II Study

Martin Hutchings, Anna Sureda Balari, Francesc Bosch, Thomas Stauffer Larsen, Paolo Corradini, Abraham Avigdor, María José Terol, Antonio Rueda Dominguez, Antonio Pinto, Alan P Skarbnik, Raul Cordoba, Judit Mészáros Joergensen, Pier Luigi Zinzani, Ronit Gurion, Neta Goldschmidt, Wilfred Leung, Donghang Li, James Relf, Maneesh Tandon, Gila Sellam, Giuseppe Gritti
Journal: Blood
Blood (2024) 144 (Supplement 1): 988.
https://doi.org/10.1182/blood-2024-194328
Published: 2024
Journal Articles

Real-World Incidence, Characteristics and Management of Cytokine Release Syndrome Induced By Chimeric Antigen Receptor T-Cell Therapy across Hematologic Malignancies

Nayan Chaudhary, Sumi Roy, Chu-Fang Lin, Maneesh Tandon, Antonia Kwan, Peter Kuebler, Ashwini Shewade
Journal: Blood
Blood (2023) 142 (Supplement 1): 5150.
https://doi.org/10.1182/blood-2023-174921
Published: 2023
Journal Articles

Glofitamab (Glofit) Plus R-CHOP Has a Favorable Safety Profile and Induces High Response Rates in Patients with Previously Untreated (1L) Large B-Cell Lymphoma (LBCL) Defined As High Risk By Circulating Tumor DNA (ctDNA) Dynamics: Preliminary Safety and Efficacy Results

Lorenzo Falchi, Fabrice Jardin, Corinne Haioun, Tomasz Wrobel, Judit Mészáros Joergensen, Mariana Bastos-Oreiro, Eric Mou, Joaquin Martinez-Lopez, L. Elizabeth Budde, Nancy L. Bartlett, Jan M. Zaucha, Alejandro Martin Garcia-Sancho, Rutanshu Shah, Nathan Rees, Ron McCord, Alexandra Bazeos, Maneesh Tandon, Michelle Doral, Ethan Troy-Barnes, Marcel Nijland
Journal: Blood
Blood (2023) 142 (Supplement 1): 858.
https://doi.org/10.1182/blood-2023-173953
Published: 2023
Journal Articles

Risk of Cytokine Release Syndrome with Glofitamab Is Predicted By an Updated Model with a Potential Clinical Application

Krishna V. Komanduri, Anton Belousov, Mark Dixon, James Relf, Maneesh Tandon
Journal: Blood
Blood (2022) 140 (Supplement 1): 9493–9495.
https://doi.org/10.1182/blood-2022-159561
Published: 2022
Journal Articles

Glofitamab (Glofit) in Combination with Polatuzumab Vedotin (Pola): Phase Ib/II Preliminary Data Support Manageable Safety and Encouraging Efficacy in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Martin Hutchings, Anna Sureda, María José Terol, Francesc Bosch Albareda, Paolo Corradini, Thomas Stauffer Larsen, Antonio Rueda Dominguez, Anesh Panchal, Alessia Bottos, David Carlile, Yanjie Wang, Audrey Filézac De L'Étang, Maneesh Tandon, Gila Sellam, Giuseppe Gritti
Journal: Blood
Blood (2021) 138 (Supplement 1): 525.
https://doi.org/10.1182/blood-2021-148359
Published: 2021
Journal Articles

Clonal Dynamics after Venetoclax-Obinutuzumab Therapy: Novel Insights from the Randomized, Phase 3 CLL14 Trial

Othman Al-Sawaf, MD, Can Zhang, PhD, Sandra Robrecht, PhD, Cameron Wilson, Maneesh Tandon, MD, Travers Ching, Anna-Maria Fink, MD, Matthias Ritgen, MD, Eugen Tausch, MD, Karl-Anton Kreuzer, MD, William Schary, PhD, Clemens-Martin Wendtner, Barbara Eichhorst, MD, Stephan Stilgenbauer, MD, Yanwen Jiang, Michael Hallek, Kirsten Fischer, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 22–23.
https://doi.org/10.1182/blood-2020-136977
Published: 2020
Journal Articles

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

Clinical Trials & Observations
Eugen Tausch, Christof Schneider, Sandra Robrecht, Can Zhang, Anna Dolnik, Johannes Bloehdorn, Jasmin Bahlo, Othman Al-Sawaf, Matthias Ritgen, Anna-Maria Fink, Barbara Eichhorst, Karl-Anton Kreuzer, Maneesh Tandon, Kathryn Humphrey, Yanwen Jiang, William Schary, Lars Bullinger, Daniel Mertens, Michele Porro Lurà, Michael Kneba, Hartmut Döhner, Kirsten Fischer, Michael Hallek, Stephan Stilgenbauer
Journal: Blood
Blood (2020) 135 (26): 2402–2412.
https://doi.org/10.1182/blood.2019004492
Published: 2020
Includes: Supplemental data
Journal Articles

High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia

Clinical Trials & Observations
Othman Al-Sawaf, Esther Lilienweiss, Jasmin Bahlo, Sandra Robrecht, Anna-Maria Fink, Michaela Patz, Maneesh Tandon, Yanwen Jiang, William Schary, Matthias Ritgen, Eugen Tausch, Stephan Stilgenbauer, Barbara Eichhorst, Kirsten Fischer, Michael Hallek, Karl-Anton Kreuzer
Journal: Blood
Blood (2020) 135 (11): 866–870.
https://doi.org/10.1182/blood.2019003451
Published: 2020
Includes: Supplemental data
Journal Articles

Rapid Improvement of Patient-Reported Outcomes with Venetoclax Plus Obinutuzumab in Patients with Previously Untreated CLL and Coexisting Conditions: A Prospective Analysis from the CLL14 Trial

Othman Al-Sawaf, MD, Brittany Gentile, PhD, Jacob Devine, MA, Kavita Sail, PhD, Maneesh Tandon, MD, Anna-Maria Fink, MD, Nadine Kutsch, MD, Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Michael Hallek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4305.
https://doi.org/10.1182/blood-2019-126542
Published: 2019
Journal Articles

Prevention and Management of Tumor Lysis Syndrome in Patients with CLL and Coexisting Conditions Treated with Venetoclax-Obinutuzumab or Chlorambucil-Obinutuzumab: Results from the Randomized CLL14 Trial

Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Sandra Robrecht, PhD, Arijit Sinha, PhD, Maneesh Tandon, MD, Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Michael Hallek, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4315.
https://doi.org/10.1182/blood-2019-126570
Published: 2019
Journal Articles

Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial

Kirsten Fischer, MD, Matthias Ritgen, Othman Al-Sawaf, MD, Sandra Robrecht, PhD, Maneesh Tandon, MD, Anna-Maria Fink, MD, Anke Schilhabel, PhD, Thomas Stübig, MD, Monika Brüggemann, MD, Yanwen Jiang, PhD, William Schary, PhD, Barbara F. Eichhorst, MD, Clemens-Martin Wendtner, MD, Eugen Tausch, Karl-Anton Kreuzer, MD PhD, Anton W Langerak, PhD, Valentin Goede, MD, Sebastian Böttcher, MD, Stephan Stilgenbauer, MD, Michael Kneba, PhD, Michael Hallek
Journal: Blood
Blood (2019) 134 (Supplement_1): 36.
https://doi.org/10.1182/blood-2019-125825
Published: 2019
Journal Articles

Phase 1b Results of a Study to Assess the Efficacy and Safety of Vismodegib in Combination with Ruxolitinib in Patients with Intermediate- or High-Risk Myelofibrosis

Stephen Couban, MDBSc, Giulia Benevolo, William Donnellan, Jennifer Cultrera, Steffen Koschmieder, Srdan Verstovsek, MD PhD, Gregory Hooper, Christian Hertig, Maneesh Tandon, Natalie Dimier, Ian Templeton, Francesco Passamonti
Journal: Blood
Blood (2017) 130 (Supplement 1): 4179.
https://doi.org/10.1182/blood.V130.Suppl_1.4179.4179
Published: 2017